In contrast, the antibody index can still be elevated (AI ≥ 1.5) years after neuroborreliosis and CSF-CXCL13 can, therefore, be used to distinguish between past/treated and active neuroborreliosis and might be a helpful marker indicating active infection and a need for therapy [49,50]. This evidence concerns the gene CXCL13 and Lyme disease.